President Trump plans to eliminate federal subsidies that currently help Medicare beneficiaries afford prescription drug premiums, according to reporting from the New York Times. The move affects millions of older Americans enrolled in Medicare Part D and Part B drug coverage programs.
Under current policy, the federal government subsidizes a portion of monthly premiums for beneficiaries, reducing out-of-pocket costs. Removing these subsidies would shift costs directly to seniors, raising their prescription drug expenses starting in 2025.
The policy targets subsidies implemented through the Inflation Reduction Act and other federal programs that helped lower drug costs for Medicare recipients. Analysts estimate the change could increase premiums by 10 to 20 percent for affected beneficiaries, depending on their specific coverage plans.
Pharmaceutical companies and insurance providers have lobbied against similar cost-control measures, arguing they undermine incentives for drug development. Conversely, patient advocacy groups and Democratic lawmakers contend that eliminating subsidies contradicts efforts to make healthcare more affordable for seniors.
Medicare enrollment covers roughly 67 million Americans, with a significant portion relying on federal premium assistance. The subsidy elimination would generate federal savings by shifting financial responsibility to individual beneficiaries rather than the government budget.
The timing remains unclear, but the administration signals the change could take effect through executive action or regulatory changes without requiring Congressional approval. Healthcare stocks, including UnitedHealth (UNH) and CVS Health (CVS), moved higher on the news, as the policy reduces government spending on prescription drug subsidies.
The move reflects the administration's broader cost-cutting agenda, though it presents political risks heading into an election cycle where healthcare affordability remains a voter priority.